Lawrenceville, N.J. — August 28, 2025 — Leads & Copy — IMUNON, Inc. (Nasdaq: IMNN) announced it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, according to a confirmation from the Nasdaq Hearings Panel. The company’s common stock will continue trading uninterrupted on The Nasdaq Capital Market.
Stacy Lindborg, Ph.D., President and CEO of IMUNON, stated that investors are assured of efficient liquidity due to the listing. Lindborg cited the recent 15% stock dividend to shareholders of record as of August 7, 2025, as a reflection of confidence in the company’s clinical pipeline and commitment to rewarding investors. This follows Phase 2 OVATION 2 trial results for IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer treatment.
IMUNON has initiated its Phase 3 OVATION 3 trial in North America and is advancing milestones across its TheraPlas® technology platform.
IMUNON is focused on advancing treatments that harness the body’s mechanisms to generate safe, effective responses across human diseases. Its lead clinical program, IMNN-001, has completed multiple clinical trials and works by instructing the body to produce cancer-fighting molecules at the tumor site. The company has also completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Contacts:
Media: Jenna Urban, CG Life, 212-253-8881, jurban@cglife.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505, peter.vozzo@icrhealthcare.com
Source: IMUNON, Inc.
